-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Advanced follicular lymphoma (FL) cannot be completely cured, and patients will relapse and progress after disease remission until refractory
.
In the past, rituximab-based immunochemotherapy was mainly used for relapsed and refractory FL, but the efficacy was not satisfactory
.
The novel anti-CD20 monoclonal antibody octuzumab has shown promising prospects in the field of FL treatment, and is expected to change the future treatment landscape of FL
.
In this regard, Yimaitong specially contacted Professor Li Xiaoling from the Lymphoma Diagnosis and Treatment Center of Liaoning Cancer Hospital to share the initial experience of the application of otuzumab
.
Professor Li Xiaoling, Director, Lymphoma Diagnosis and Treatment Center, Liaoning Cancer Hospital Member of the Standing Committee of the Cancer Alliance, Member of the CSCO Small Cell Lung Cancer Expert Committee, Chairman of the Lymphoma Professional Committee of the Liaoning Provincial Anti-Cancer Association, Chairman of the Thoracic Tumor Committee of the Liaoning Provincial Cell Biology Society Member of the Standing Committee of the Liaoning Anti-Cancer Association Tumor Metastasis Professional Committee Member of the Standing Committee of the Liaoning Provincial Anti-Cancer Association, Vice Chairman of the Lymphatic Foundation and Immunology Branch of the Liaoning Provincial Association of Immunology Yi Maitong: Could you please introduce the current status of FL treatment, and what unmet clinical needs are still in patients with FL? Professor Li Xiaoling has been in the chemotherapy era for the past 20 years.
Rituximab-based regimens have always been the first choice for B-cell lymphoma patients.
The overall survival rate of patients has been significantly improved, but traditional treatment regimens cannot meet actual clinical needs.
, especially for relapsed and refractory patients, there is an urgent need for innovative drugs or innovative treatment options to improve patient survival
.
Due to the vast territory of China and the uneven development of various regions, the five-year survival rate of lymphoma patients in China is still low.
There is a clear disparity in the five-year OS rate of 60%-70% in patients with lymphoma
.
As the most common indolent non-Hodgkin lymphoma (iNHL), FL has a slow progression and most patients cannot be completely cured.
The unmet clinical needs are mainly in early progression, refractory relapse, and transformation into large B-cell lymphoma.
three aspects
.
Disease recurrence is an unavoidable reality for FL patients.
Our department once treated a patient with advanced FL who received first-line R-CHOP (rituximab combined with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone).
) The disease recurred in the sixth year after treatment, and multiple enlarged lymph nodes appeared in the left armpit and right groin
.
For such relapsed and rapidly progressing patients, medication options are limited at this time, and the efficacy of FL relapse is very important.
Repeated relapse will seriously affect the patient's survival
.
Yi Mai Tong: Could you please talk about the efficacy of otuzumab in the treatment of FL based on the actual drug experience of this patient? Professor Li Xiaoling's efficacy of ortuzumab in the treatment of FL has been verified in multiple clinical studies
.
The global phase III GALLIUM study in treatment-naïve FL patients showed that compared with rituximab plus chemotherapy, octuzumab combined with chemotherapy reduced the risk of recurrence and death by 34% in patients with early-stage disease The risk of progression decreased by 46%
.
In patients with relapsed and refractory FL, the global phase III GADOLIN study showed otuzumab plus bendamustine (GB) versus bendamustine monotherapy in rituximab-resistant iNHL patients After treatment, the risk of disease progression and death in the combination therapy group was reduced by 49% compared with monotherapy; in addition, in the GALEN phase II multicenter clinical study, for relapsed and refractory FL patients, otuzumab combined with lenalidomide (G-Len) also demonstrated excellent efficacy, with a 2-year progression-free survival (PFS) rate of 65%
.
The FL patient we treated was first treated with the R-CHOP regimen after relapse.
After three cycles of rituximab combined with chemotherapy, the patient developed resistance to rituximab, and the lesions no longer shrunk
.
Based on the excellent performance of the global phase III GADOLIN study on the rituximab-resistant population and the patient's strong willingness to treat, G-CHOP was switched to treatment
.
The good news is that this FL patient was looking forward to the launch of octuzumab in China as early as the beginning of last year, and now octuzumab has been approved for marketing in China and entered into medical insurance, becoming the treatment for more Chinese FL patients.
New selection
.
Yimaitong: Data from previous clinical studies have shown that Otuzumab treatment did not bring new and unexpected toxicities to patients
.
Can you share your experience with the safety of otuzumab? During the six cycles of first-line R-CHOP treatment in 2015, this FL patient from our department, Professor Li Xiaoling, suffered from toothache and numbness in both legs after each chemotherapy
.
However, the patient did not experience any adverse reactions during the first four infusions of otuzumab, and there was no adverse reactions such as toothache and numbness in the legs after the end of chemotherapy, which made our clinicians more We firmly believe in the good safety of otuzumab
.
The GALLIUM study and preliminary clinical practice have confirmed the safety of octuzumab for the treatment of FL, and the GAZELLE study evaluated the safety of octuzumab 90min rapid infusion, and the results suggest that FL patients start from the second cycle Initially, octuzumab was given as a 90-min bolus infusion (SDI) with a well-tolerated safety profile
.
Analysis at a recent ASH meeting showed that 90-minute bolus infusion of octuzumab has become the first choice for healthcare workers, minimizing the burden of treatment and improving patient comfort without compromising health-related quality of life
.
Yimaitong: In view of the excellent efficacy and safety benefits of octuzumab, can you talk about the future application of octuzumab in Chinese FL patients? Professor Li Xiaoling Based on the excellent efficacy and safety benefits in the global phase III GADOLIN study, otuzumab has been approved in many countries and regions around the world for the indication of relapsed and refractory FL.
The 2021 edition of the Chinese CSCO Lymphoma Diagnosis and Treatment Guidelines Otuzumab is recommended for the treatment of relapsed and refractory FL
.
Following the concept of "early use of good drugs", advancing the number of treatment lines of otuzumab is an effective option to reduce the progression/recurrence of FL
.
Compared with R-chemotherapy, the G-chemotherapy regimen reduced the risk of progression, recurrence and death by 34% and the relative risk of early progression (POD24) events by 46% in treatment-naïve FL patients, currently based on octuzumab The treatment regimen has set a new standard in the first-line treatment of follicular lymphoma
.
In June 2021, Ortuzumab was approved in China for the first-line induction and maintenance treatment of FL, and it took only half a year to be included in the medical insurance list.
On January 1 this year, the medical insurance reimbursement was officially implemented.
The reimbursement scope includes induction and maintenance treatment stages.
Therefore, octuzumab has become the first targeted drug in the field of follicular lymphoma to achieve full coverage of induction and maintenance therapy, filling the medical insurance gap for FL maintenance therapy in the catalog
.
The median survival of FL patients can be as long as 10 years, and the drugs available to patients within 10 years are relatively limited.
The application of otuzumab in first-line treatment can prolong PFS, improve the quality of life, and reduce the economic burden of multiple recurrences.
has important clinical significance
.
With the increased availability of drugs, more Chinese FL patients are expected to receive more efficient and safe treatment from octuzumab, and octuzumab-based treatment regimens are gradually becoming a new and unanimously recognized option for the treatment of FL
.
It is expected that in the future, octuzumab can carry out relevant real-world research in the Chinese population, accumulate Chinese experience, further improve the survival status of Chinese lymphoma patients, and bring more benefits to the majority of Chinese lymphoma patients
.
★ Scan the QR code below to enter the "Mystery Exploration" channel ★ Click "Read the original text" to enter the "Mystery Exploration" channel!
.
In the past, rituximab-based immunochemotherapy was mainly used for relapsed and refractory FL, but the efficacy was not satisfactory
.
The novel anti-CD20 monoclonal antibody octuzumab has shown promising prospects in the field of FL treatment, and is expected to change the future treatment landscape of FL
.
In this regard, Yimaitong specially contacted Professor Li Xiaoling from the Lymphoma Diagnosis and Treatment Center of Liaoning Cancer Hospital to share the initial experience of the application of otuzumab
.
Professor Li Xiaoling, Director, Lymphoma Diagnosis and Treatment Center, Liaoning Cancer Hospital Member of the Standing Committee of the Cancer Alliance, Member of the CSCO Small Cell Lung Cancer Expert Committee, Chairman of the Lymphoma Professional Committee of the Liaoning Provincial Anti-Cancer Association, Chairman of the Thoracic Tumor Committee of the Liaoning Provincial Cell Biology Society Member of the Standing Committee of the Liaoning Anti-Cancer Association Tumor Metastasis Professional Committee Member of the Standing Committee of the Liaoning Provincial Anti-Cancer Association, Vice Chairman of the Lymphatic Foundation and Immunology Branch of the Liaoning Provincial Association of Immunology Yi Maitong: Could you please introduce the current status of FL treatment, and what unmet clinical needs are still in patients with FL? Professor Li Xiaoling has been in the chemotherapy era for the past 20 years.
Rituximab-based regimens have always been the first choice for B-cell lymphoma patients.
The overall survival rate of patients has been significantly improved, but traditional treatment regimens cannot meet actual clinical needs.
, especially for relapsed and refractory patients, there is an urgent need for innovative drugs or innovative treatment options to improve patient survival
.
Due to the vast territory of China and the uneven development of various regions, the five-year survival rate of lymphoma patients in China is still low.
There is a clear disparity in the five-year OS rate of 60%-70% in patients with lymphoma
.
As the most common indolent non-Hodgkin lymphoma (iNHL), FL has a slow progression and most patients cannot be completely cured.
The unmet clinical needs are mainly in early progression, refractory relapse, and transformation into large B-cell lymphoma.
three aspects
.
Disease recurrence is an unavoidable reality for FL patients.
Our department once treated a patient with advanced FL who received first-line R-CHOP (rituximab combined with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone).
) The disease recurred in the sixth year after treatment, and multiple enlarged lymph nodes appeared in the left armpit and right groin
.
For such relapsed and rapidly progressing patients, medication options are limited at this time, and the efficacy of FL relapse is very important.
Repeated relapse will seriously affect the patient's survival
.
Yi Mai Tong: Could you please talk about the efficacy of otuzumab in the treatment of FL based on the actual drug experience of this patient? Professor Li Xiaoling's efficacy of ortuzumab in the treatment of FL has been verified in multiple clinical studies
.
The global phase III GALLIUM study in treatment-naïve FL patients showed that compared with rituximab plus chemotherapy, octuzumab combined with chemotherapy reduced the risk of recurrence and death by 34% in patients with early-stage disease The risk of progression decreased by 46%
.
In patients with relapsed and refractory FL, the global phase III GADOLIN study showed otuzumab plus bendamustine (GB) versus bendamustine monotherapy in rituximab-resistant iNHL patients After treatment, the risk of disease progression and death in the combination therapy group was reduced by 49% compared with monotherapy; in addition, in the GALEN phase II multicenter clinical study, for relapsed and refractory FL patients, otuzumab combined with lenalidomide (G-Len) also demonstrated excellent efficacy, with a 2-year progression-free survival (PFS) rate of 65%
.
The FL patient we treated was first treated with the R-CHOP regimen after relapse.
After three cycles of rituximab combined with chemotherapy, the patient developed resistance to rituximab, and the lesions no longer shrunk
.
Based on the excellent performance of the global phase III GADOLIN study on the rituximab-resistant population and the patient's strong willingness to treat, G-CHOP was switched to treatment
.
The good news is that this FL patient was looking forward to the launch of octuzumab in China as early as the beginning of last year, and now octuzumab has been approved for marketing in China and entered into medical insurance, becoming the treatment for more Chinese FL patients.
New selection
.
Yimaitong: Data from previous clinical studies have shown that Otuzumab treatment did not bring new and unexpected toxicities to patients
.
Can you share your experience with the safety of otuzumab? During the six cycles of first-line R-CHOP treatment in 2015, this FL patient from our department, Professor Li Xiaoling, suffered from toothache and numbness in both legs after each chemotherapy
.
However, the patient did not experience any adverse reactions during the first four infusions of otuzumab, and there was no adverse reactions such as toothache and numbness in the legs after the end of chemotherapy, which made our clinicians more We firmly believe in the good safety of otuzumab
.
The GALLIUM study and preliminary clinical practice have confirmed the safety of octuzumab for the treatment of FL, and the GAZELLE study evaluated the safety of octuzumab 90min rapid infusion, and the results suggest that FL patients start from the second cycle Initially, octuzumab was given as a 90-min bolus infusion (SDI) with a well-tolerated safety profile
.
Analysis at a recent ASH meeting showed that 90-minute bolus infusion of octuzumab has become the first choice for healthcare workers, minimizing the burden of treatment and improving patient comfort without compromising health-related quality of life
.
Yimaitong: In view of the excellent efficacy and safety benefits of octuzumab, can you talk about the future application of octuzumab in Chinese FL patients? Professor Li Xiaoling Based on the excellent efficacy and safety benefits in the global phase III GADOLIN study, otuzumab has been approved in many countries and regions around the world for the indication of relapsed and refractory FL.
The 2021 edition of the Chinese CSCO Lymphoma Diagnosis and Treatment Guidelines Otuzumab is recommended for the treatment of relapsed and refractory FL
.
Following the concept of "early use of good drugs", advancing the number of treatment lines of otuzumab is an effective option to reduce the progression/recurrence of FL
.
Compared with R-chemotherapy, the G-chemotherapy regimen reduced the risk of progression, recurrence and death by 34% and the relative risk of early progression (POD24) events by 46% in treatment-naïve FL patients, currently based on octuzumab The treatment regimen has set a new standard in the first-line treatment of follicular lymphoma
.
In June 2021, Ortuzumab was approved in China for the first-line induction and maintenance treatment of FL, and it took only half a year to be included in the medical insurance list.
On January 1 this year, the medical insurance reimbursement was officially implemented.
The reimbursement scope includes induction and maintenance treatment stages.
Therefore, octuzumab has become the first targeted drug in the field of follicular lymphoma to achieve full coverage of induction and maintenance therapy, filling the medical insurance gap for FL maintenance therapy in the catalog
.
The median survival of FL patients can be as long as 10 years, and the drugs available to patients within 10 years are relatively limited.
The application of otuzumab in first-line treatment can prolong PFS, improve the quality of life, and reduce the economic burden of multiple recurrences.
has important clinical significance
.
With the increased availability of drugs, more Chinese FL patients are expected to receive more efficient and safe treatment from octuzumab, and octuzumab-based treatment regimens are gradually becoming a new and unanimously recognized option for the treatment of FL
.
It is expected that in the future, octuzumab can carry out relevant real-world research in the Chinese population, accumulate Chinese experience, further improve the survival status of Chinese lymphoma patients, and bring more benefits to the majority of Chinese lymphoma patients
.
★ Scan the QR code below to enter the "Mystery Exploration" channel ★ Click "Read the original text" to enter the "Mystery Exploration" channel!
